Business
InvestmentPitch Media Video Discusses Resverlogix' Active Discussions with the Kingdom of Morocco's Ministry of Health for the Launch of COVID-19 Clinical Studies Involving Apabetalone - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2021) - Resverlogix Corp. (TSX: RVX...
About this update from Resverlogix Corp.
[{"type":"text","content":"InvestmentPitch Media Video Discusses Resverlogix' Active Discussions with the Kingdom of Morocco's Ministry of Health for the Launch of COVID-19 Clinical Studies Involving Apabetalone - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - November 2, 2021) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF), a world leader in epigenetics, or gene regulation, is in active discussions with the Kingdom of Morocco's Ministry of Health for possible Phase 2 COVID-19 clinical studies within their hospitals using apabetalone, Resverlogix' first-in-class drug.InvestmentPitch.com has produced a \"video\" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Resverlogix\" in the search box. Cannot view this video? Visit:http://www.investmentpitch.com/video/1_eb4lc99n/Resverlogix-in-active-discussions-with-the-Kingdom-of-Moroccos-Ministry-of-Health-for-the-launch-of-COVID-19-clinical-studies-involving-apabetaloneDonald McCaffrey, President & CEO of Resverlogix, stated: \"We are pleased to collaborate with the Kingdom of Morocco's Ministry of Health under the leadership of Professor Bouchra Meddah, Director of Medicines and Pharmacy, for the possible launch of COVID-19 clinical studies with our novel epigenetic drug apabetalone. It is imperative to clear hospital beds of COVID-19 patients to allow urgent surgeries and other necessities to take place, which will contribute to reopening and strengthening the economy in the Kingdom of Morocco.\"Professor Bouchra Meddah, Director of Medicines and Pharmacy, Ministry of Health in the Kingdom of Morocco, added: \"The Kingdom of Morocco's Ministry of Health is pleased to be collaborating with Resverlogix on this important global initiative that has tragically impacted so many people worldwide. Our team was very impressed by the publications from Cell Journal, Nature report, along with Health Canada and FDA approvals for COVID-19 clinical trials. Our Ministry has also recognized the FDA's granting to Resverlogix the coveted Breakthrough Therapy Designation for apabetalone in a cardiovascular indication.\"Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company developing first-in-class therapies for the benefit of patients with chronic disease. The company aims to improve patients' lives by re...